Ocrevus and Pancreatitis - a phase IV clinical study of FDA data

Summary:

Pancreatitis is reported as a side effect among people who take Ocrevus (ocrelizumab), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Pantoprazole, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Pancreatitis when taking Ocrevus. It is created by eHealthMe based on reports of 56,539 people who have side effects when taking Ocrevus from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Pancreatitis?

Pancreatitis (inflammation of pancreas) is found to be associated with 1,760 drugs and 2,027 conditions by eHealthMe. Check the latest studies of Pancreatitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

56,539 people reported to have side effects when taking Ocrevus.
Among them, 130 people (0.23%) have Pancreatitis.

Among these 130 people:

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and have Pancreatitis?

- Check whether Pancreatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ocrevus:

Ocrevus (56,583 reports)

Pancreatitis treatments and more:

Pancreatitis (62,704 reports)

How severe was Pancreatitis and when was it recovered:

Pancreatitis in Ocrevus

Expand to all the drugs that have ingredients of ocrelizumab:

Pancreatitis and drugs with ingredients of ocrelizumab (153 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pancreatitis:

Pancreatitis (1,760 drugs)

Browse all the conditions that are associated with Pancreatitis:

Pancreatitis (2,027 conditions)

Related publications that referenced our studies

Sirkeci, ?., Sirkeci, E. E., & Ta?el, B. , "Rivaroxaban-induced acute pancreatitis", The European Research Journal, 2018 Jan .
Liao, K. F., Huang, P. T., Lin, C. C., Lin, C. L., & Lai, S. W., "Fluvastatin use and risk of acute pancreatitis: a population-based case-control study in Taiwan", Biomedicine, 2014 Jan .
Arshad F, Ladakhi Y, Khan MA, "A rare case of carbamazepine induced pancreatitis", International Journal of Students’ Research, 2013 Jul .
Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK, "A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis", Journal of Young Pharmacists, 2013 Jun .
Sirkeci, ?., Sirkeci, E. E., & Ta?el, B. , "Rivaroxaban-induced acute pancreatitis", The European Research Journal, 2018 Jan .
Liao, K. F., Huang, P. T., Lin, C. C., Lin, C. L., & Lai, S. W., "Fluvastatin use and risk of acute pancreatitis: a population-based case-control study in Taiwan", Biomedicine, 2014 Jan .
Arshad F, Ladakhi Y, Khan MA, "A rare case of carbamazepine induced pancreatitis", International Journal of Students’ Research, 2013 Jul .
Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK, "A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis", Journal of Young Pharmacists, 2013 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab (the active ingredients of Ocrevus) and Ocrevus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.